Randomized trial: Adjuvant capecitabine in triple-negative breast cancer

Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial – JAMA

Commentaries: Capecitabine maintenance may improve TNBC outcomes – medwire News

Commentary on Twitter

In this RCT, low-dose #capecitabine maintenance therapy for 1y resulted in improved 5-y disease-free survival vs observation among women with early-stage triple-negative breast cancer who received standard adjuvant treatment https://t.co/sIgxUSjaYe #BCSM #SABCS20 #VisualAbstract

— JAMA (@JAMA_current) January 6, 2021